다른 서비스와 비교했을 때 MBOT 의 PB 비율은 어느 정도인가요?

MBOT은 Price-To-Book 비율(4.4x)을 기준으로 볼 때 동종 업체의 평균(0.7x)과 비교했을 때 비쌉니다.

MBOT 의 PB 비율은 US Medical Equipment 업계의 다른 회사와 어떻게 비교됩니까?

MBOT 은 US Medical Equipment 과 비교하여 Price-To-Book 비율( 4.4 x)을 기준으로 비용이 많이 듭니다. Medical Equipment 업계 평균( 2.5 x).

MBOT 의 PB 비율과 공정 PB 비율은 어떻게 되나요? 회사의 예상 수익 성장률, 이익 마진 및 기타 위험 요소를 고려한 예상 PB 비율입니다.

평가 분석을 위한 MBOT 의 Price-To-Book 공정 비율을 계산하기에는 데이터가 부족합니다.

미래 현금 흐름을 볼 때 MBOT 의 공정 가격은 얼마인가요? 이 추정에는 할인된 현금흐름 모델을 사용합니다.

평가 분석을 위해 MBOT 의 공정 가치를 계산하기에는 데이터가 부족합니다.

애널리스트의 12개월 전망은 무엇이며 컨센서스 목표가에 대한 통계적 신뢰도가 있나요?

가격 예측을 표시하기에는 데이터가 부족합니다.

Microbot Medical (Nasdaq:MBOT) - 주가, 뉴스 및 분석

MBOT 주식 개요

마이크로봇 메디컬은 임상 전 단계의 의료기기 회사로 최소 침습 수술 분야를 대상으로 로봇 내강 내 수술 장치를 연구, 설계, 개발하는 기업입니다. 자세한 내용

MBOT 기본 분석
눈송이 점수
가치 평가	0/6
미래 성장	0/6
과거 실적	0/6
재무 상태	4/6
배당금	0/6

위험 분석

수익이 1백만 달러 미만인 경우 ( $0 )

cash runway 경력이 1년 미만입니다.

지난 5년간 매년 수익이 8.3% 씩 감소했습니다.

지난 1년 동안 주주가 희석되었습니다.

+ 1 더 많은 위험

Microbot Medical Inc. 경쟁사

Cue Health

NasdaqCM:HLTH

US$14.7m

Ekso Bionics Holdings

NasdaqCM:EKSO

US$15.8m

Lifeward

NasdaqCM:LFWD

US$16.4m

STRATA Skin Sciences

NasdaqCM:SSKN

US$12.9m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Microbot Medical
과거 주가
현재 주가	US$0.98
52주 최고치	US$2.35
52주 최저치	US$0.82
베타	1.63
11개월 변경	-2.97%
3개월 변경 사항	-2.92%
1년 변경 사항	-28.99%
33년 변화	-81.89%
5년 변화	-80.28%
IPO 이후 변화	-99.36%

최근 뉴스 및 업데이트

Recent updates

Is Microbot Medical (NASDAQ:MBOT) In A Good Position To Invest In Growth?

Dec 30

Is Microbot Medical (NASDAQ:MBOT) In A Good Position To Invest In Growth?

Sep 01

Here's Why We're A Bit Worried About Microbot Medical's (NASDAQ:MBOT) Cash Burn Situation

Dec 28

Companies Like Microbot Medical (NASDAQ:MBOT) Are In A Position To Invest In Growth

Dec 24

We Think Microbot Medical (NASDAQ:MBOT) Can Afford To Drive Business Growth

Aug 27

Companies Like Microbot Medical (NASDAQ:MBOT) Are In A Position To Invest In Growth

May 12

We Think Microbot Medical (NASDAQ:MBOT) Can Afford To Drive Business Growth

Jan 27

Microbot Medical's study of surgical robotic system meets endpoints

Jan 14

주주 수익률

	MBOT	US Medical Equipment	US 마켓
7D	5.7%	1.5%	2.2%
1Y	-29.0%	20.9%	31.7%

수익률 대 산업: MBOT 지난 1년 동안 20.9 %를 반환한 US Medical Equipment 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: MBOT 지난 1년 동안 31.7 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is MBOT's price volatile compared to industry and market?
MBOT volatility
MBOT Average Weekly Movement	6.9%
Medical Equipment Industry Average Movement	8.1%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

안정적인 주가: MBOT 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: MBOT 의 주간 변동성은 지난 1년 동안 13% 에서 7% 로 감소했습니다.

회사 소개

설립	직원	CEO	웹사이트
2010	22	Harel Gadot	microbotmedical.com

마이크로봇 메디컬은 전임상 의료 기기 회사로 최소 침습 수술 분야를 겨냥한 로봇 내강 수술 장치를 연구, 설계, 개발하는 기업입니다. 이 회사는 의사가 카테터 삽입 실험실 외부에서 카테터 기반 시술을 수행하고 방사선 노출, 신체적 긴장, 교차 오염의 위험을 피하여 심혈관, 말초 및 신경 혈관 공간에서 사용할 수 있는 혈관 내 로봇 수술 시스템인 LIBERTY를 제공합니다. 또한 앵커링 메커니즘과 통합 마이크로 카테터를 갖춘 관강 내 혈관 재개통 장치 분야의 지적 재산 및 기술인 NovaCross를 제공합니다.

Microbot Medical Inc. 기본 사항 요약

Microbot Medical 의 수익과 매출은 시가총액과 어떻게 비교하나요?
MBOT 기본 통계
시가총액	US$15.74m
수익(TTM)	-US$11.20m
수익(TTM)	n/a

0.0x

P/S 비율

-1.5x

P/E 비율

MBOT 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
MBOT 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$11.21m
수익	-US$11.20m

최근 보고된 수익

Sep 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.66
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

MBOT 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

MBOT 주식 개요

위험 분석

Microbot Medical Inc. 경쟁사

NasdaqCM:HLTH

US$14.7m

NasdaqCM:EKSO

US$15.8m

NasdaqCM:LFWD

US$16.4m

NasdaqCM:SSKN

US$12.9m

가격 내역 및 성능

최근 뉴스 및 업데이트

New major risk - Financial position

Microbot Medical Inc., Annual General Meeting, Dec 17, 2024

Microbot Medical Inc. Announces Successful Completion of Its Pivotal Human Clinical Trial

Microbot Medical Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Microbot Medical Inc. Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System

Microbot Medical Inc. Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center

Recent updates

New major risk - Financial position

Microbot Medical Inc., Annual General Meeting, Dec 17, 2024

Microbot Medical Inc. Announces Successful Completion of Its Pivotal Human Clinical Trial

Microbot Medical Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Microbot Medical Inc. Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System

Microbot Medical Inc. Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center

Microbot Medical Enrolled the First Patient in Its Pivotal Human Clinical Trial

Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $4.819905 million.

Microbot Medical Inc. announced that it has received $1.762502 million in funding

New major risk - Shareholder dilution

Microbot Medical Inc. has completed a Follow-on Equity Offering in the amount of $2.350004 million.

Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $2.350004 million.

New minor risk - Share price stability

Microbot Medical Announces Positive Results from the First Phase of Its Collaboration with Corewell Health

Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US

Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving All Associated Legal Matters

New major risk - Shareholder dilution

Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study

Is Microbot Medical (NASDAQ:MBOT) In A Good Position To Invest In Growth?

Microbot Medical Announces Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Met

Microbot Medical Announces the Successful Completion of its GLP Pivotal Pre-Clinical Study

Microbot Medical Inc. Announces Executive Changes

Microbot Medical Inc. Successfully Completed Integral Part of the Verification and Validation Process

Microbot Medical Reveals Successful Short Term Follow Up Outcomes from Its Pivotal Pre-Clinical Study

Microbot Medical Inc. Announces Grant of Summary Judgment in its Favor and Dismissal of Counterclaim Against Company

Microbot Medical Inc. Announces Successful Initial Outcomes from its Pivotal Pre-Clinical Study with the LIBERTY Robotic Surgical System

Microbot Medical Inc., Annual General Meeting, Nov 02, 2023

Is Microbot Medical (NASDAQ:MBOT) In A Good Position To Invest In Growth?

Price target decreased by 60% to US$8.00

Microbot Medical Inc. Appoints Francois H. Cornelis to its Scientific Advisory Board

Microbot Medical Inc. Announces the Expansion of its Global IP Portfolio by Receiving a Grant of Protection from the Japan Patent Office

New major risk - Shareholder dilution

Microbot Medical Receives Non-Dilutive Grant from the Israel Innovation Authority Supporting the Development of the Manufacturing Process for Its Endovascular Surgical Robotic System

LIBERTY Robotic Surgical System Achieved Additional Milestone in its Path to First in Human and Regulatory Process

Microbot Medical Inc. announced delayed 10-Q filing

Microbot Medical Initiates Preparations for First-In-Human (Fih) Cases in Brazil for the Liberty® Robotic System

Price target decreased by 58% to US$8.00

Microbot Medical Inc. Announces Final Data from Its Recent Animal Study

Microbot Medical Inc. Announces Liberty Robotic System Surpasses 100Th Catheterization

Here's Why We're A Bit Worried About Microbot Medical's (NASDAQ:MBOT) Cash Burn Situation

Microbot Medical Inc.’s Proprietary LIBERTY® Robotic System Receives Third Patent Allowance in Israel

Microbot Medical’s Novel LIBERTY® Robotic System Continues to be Validated with Latest U.S. Design Patent Allowance

High number of new directors

Microbot Medical Inc. Receives Additional Patent Allowance in Israel for the LIBERTY(R) Robotic System

Microbot Medical Inc Appoints Thierry Jacques De Baère to its Scientific Advisory Board

Microbot Medical Accomplishes the Next-Step in the Regulatory Process for the Liberty® Robotic System

Microbot Medical Completes Glp Animal Study for the LIBERTY Robotic System

Microbot Medical Receives Patent Allowance in Israel for the Liberty® Robotic System

Microbot Medical Inc. (NasdaqCM:MBOT) entered into an Asset Purchase Agreement to acquire Assets from Nitiloop.

Microbot Medical acquires Nitiloop, terms undisclosed

Microbot Medical Inc. Announce Strategic Addition to Scientific Advisory Board Appointment

Microbot Medical Inc. Announces Ripal T. Gandhi Has Joined Its Scientific Advisory Board

Microbot Medical Inc. Announces Vincent Vidal Has Joined Its Scientific Advisory Board

Here's Why We're Watching Microbot Medical's (NASDAQ:MBOT) Cash Burn Situation

Microbot Medical Commences its First Step in the Anticipated Regulatory Process for its LIBERTY Robotic System

Microbot Medical Inc. Appoints Sebastian Flacke to its Scientific Advisory Board

Microbot Medical Inc. Medical Secures Design Patent Grant in Europe for the LIBERTY Robotic System

Microbot Medical Confirms GLP Pre-Clinical Trial Is on Track to Commence Later This Month

Microbot Medical confirms GLP trial on track to begin later this month

Microbot Medical Inc., Annual General Meeting, Sep 21, 2022